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1. Introduction 
Coronary artery disease (CAD) is a leading cause of death in the world and one of the 
major risk factors for CAD is dyslipidemia. In understanding dyslipidemia and 
developing therapeutics, animal models, especially genetically modified animals, have 
played important roles and contributed greatly to progress in this field. Before the 
development of genetically modified animals, the Watanabe heritable hyperlipidemic 
(WHHL) rabbit, the first animal model for familial hypercholesterolemia, developed by 
Yoshio Watanabe in 1980 (Watanabe, 1980), helped to verify a low-density lipoprotein 
(LDL) receptor-pathway in vivo and to clarify lipoprotein metabolism in humans 
(Goldstein, 1983), in addition to the process by which atherosclerosis develops (Shiomi, 
2009). Furthermore, WHHL rabbits have contributed to the development of 
hypocholesterolemic agents, statins, (Watanabe, 1981; Tsujita, 1986) and to clarifying 
anti-atherosclerotic effects (Watanabe, 1988; Shiomi, 1995; 2009). In the present, WHHL 
rabbits were improved by selective breeding to produce the WHHLMI strain, which 
suffers from severe and vulnerable coronary atheromatous plaques and myocardial 
infarction due to coronary occlusion with progression of atherosclerotic plaques (Shiomi, 
2003). However, WHHL or WHHLMI rabbits were not suitable for studying the role of 
genes in lipid metabolism, because it is difficult to apply genetic modification techniques 
to rabbits.  
The first transgenic mice were developed in 1982 (Gordon, 1982) and the first knockout 
mice in 1984 (Bradley, 1984). Genetically modified mice are commonly used to study 
lipoprotein metabolism and atherosclerosis. The first transgenic mice for lipoprotein 
metabolism were LDLR-overexpressing mice, developed in 1988 (Hofmann, 1988), and the 
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first knockout (KO) mice for lipoprotein metabolism were apolipoprotein (apo) E-KO 
mice, developed in 1992 (Zhang, 1992). Thereafter, numerous genetically modified mouse 
models were produced and these mice have contributed to a better understanding of 
lipoprotein metabolism. However, we should recognize that the lipoprotein metabolism 
of genetically modified mice is not entirely the same as that of humans, despite 
hyperlipidemia or hypercholesterolemia. In addition, recent studies have demonstrated 
different phenotypes manifested in mice and rabbits after the same gene transfer (Fan, 
2003). The first transgenic rabbit was developed in 1985 (Hammer, 1985) and the first 
transgenic rabbit for lipoprotein metabolism, the hepatic lipase-overexpressing rabbit, 
was developed in 1994 (Fan, 1994). The differences in phenotype following gene transfer 
between mice and rabbits may be due to species differences in lipoprotein metabolism. 
When using animal models in experimental research, one has to be careful interpreting 
the results. Since other chapters explain in detail the functions of enzymes, 
apolipoproteins, and receptors relating to lipoprotein metabolism, this chapter 
concentrates on introducing various genetically modified animals and species differences 
in phenotype expression after gene modification for researchers wishing to study 
lipoprotein metabolism. 
2. Species differences in lipoprotein metabolism 
2.1. Species differences in lipoprotein profiles 
Fig. 1 shows lipoprotein profiles of mice, rabbits, and humans analysed with high 
performance liquid chromatography (HPLC). The main lipoprotein is LDL in human 
normal subjects but high-density lipoprotein (HDL) in wild-type mice. LDL is increased 
markedly in the plasma of patients with hypercholesterolemia (Yin, 2012) and WHHLMI 
rabbits, but lipoproteins that elute at the position of very low-density lipoprotein (VLDL) 
are increased in apoE-deficient mice, one of the most commonly used genetically modified 
mice (Piedrahita, 1992). Although serum lipid levels and the lipoprotein profile of apoE-
KO mice vary depending on the colony, the lipoprotein profile of apoE-KO mice is similar 
to that of cholesterol-fed rabbits (Yin, 2012). In LDL receptor (LDLR)-deficient 
individuals, LDL increased markedly in patients (familial hypercholesterolemia) and 
rabbits (WHHLMI rabbits) despite a normal diet or chow, while plasma LDL levels were 
not so high in homozygous LDLR-KO mice fed standard chow as described by Ishibashi 
et al. (1993), although serum lipid levels and lipoprotein profiles of LDLR-KO mice vary 
in each colony similar to those of apoE-KO mice. After consumption of a cholesterol-
enriched diet, plasma cholesterol levels increased markedly in LDLR-KO mice, similar to 
FH patients and WHHL rabbits, but the increased lipoprotein fraction eluted at the 
position of VLDL (Ishibashi, 1994) and the lipoprotein profile was similar to that of 
cholesterol-fed rabbits (Yin, 2012). These differences in lipoprotein profiles between mice 
and humans or rabbits are probably due to the species differences in lipoprotein 
metabolism.  
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Figure 1. Lipoprotein profiles of a healthy human, rabbits, and mice. Lipoprotein profiles were 
analyzed with high performance liquid chromatography. Animals were fed standard chow.  Red lines 
indicate cholesterol and blue lines indicate triglyceride 
2.2. Lipoprotein metabolism in mice and rats 
Fig. 2 shows a schematic diagram of lipoprotein metabolism in wild-type mice and rats. 
Dietary cholesterol is absorbed at the intestine mediated by Niemann-Pick C1-like 1 
protein (NPC1L1) (Altmann, 2004) and ATP-binding cassette transporters (ABC) (Berge, 
2000). Dietary fat is hydrolyzed to form monoglycerides and fatty acids in the intestine. 
These lipolytic products are translocated to the enterocyte membrane, and migrate to the 
endoplasmic reticulum. Overexpression of the tis7 gene in mice increases triglyceride 
absorption (Wang, 2009), and the transport of saturated fatty acids and cholesterol is 
decreased in fatty acid-binding protein (FABP)-KO mice (Newberry, 2009). 
Monoglycerides and fatty acids are re-esterified into triglycerides at the cytoplasmic 
surface of the endoplasmic reticulum. Synthesized triglycerides, cholesterol, and 
apolipoproteins are assembled in chylomicron particles. In the process of chylomicron 
assembly, MTP assists in binding lipids to apolipoproteins (Hussain, 2012). Since the apoB 
mRNA editing enzyme (apobec-1) functions at the intestinal wall, chylomicron particles 
contain apoB-48 as a major apolipoprotein but do not contain apoB-100. Chylomicron 
particles are released into the lacteal vessel. ApoB-48 is a marker of exogenous lipoprotein 
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in humans and rabbits. At the capillary of peripheral tissue, chylomicron particles release 
free fatty acids (FFA) to adipose tissues mediated by lipoprotein lipase (LPL) and are 
converted to chylomicron remnants (Goldstein, 1983). Chylomicron remnants rapidly 
disappear from the circulation through apoE-receptors (apoER, remnant receptors) 
expressed in the liver. The metabolism of exogenous lipoproteins is preserved across 
species. In endogenous lipoprotein metabolism, cholesterol and other lipids synthesized 
in the liver are assembled in VLDL particles. Since apobec-1 is not expressed in the liver in 
humans and rabbits, VLDL particles contain apoB-100 but not apoB-48. However, VLDL 
particles of mice and rats contain both apoB-100 and apoB-48, because apobec-1 is 
expressed in the liver (Greeve, 1993). At the capillary in peripheral tissue, VLDL particles 
release FFA similar to chylomicron particles, which is then transformed into intermediate-
density lipoprotein (IDL) (Goldstein, 1983). Part of the remaining VLDL particles and/or 
partially catalyzed VLDL particles bind to VLDL receptors expressed in peripheral tissue 
(Takahashi, 2004). Finally, apoB-48-containing VLDL and IDL in mice and rats disappear 
from the circulation through apoER expressed in the liver similar to chylomicron 
remnants. Some IDL particles containing apoB-100 bind to LDLRs in the liver, the rest 
release fatty acids via hepatic lipase (HL) and are transformed into LDL. LDL particles 
bind to LDLRs expressed at the surface of somatic cells. Therefore, a marker of 
endogenous lipoproteins is apoB-100 in humans and rabbits but endogenous lipoproteins 
of mice and rats contain both apoB-100 and apoB-48. Since the fractional catabolic rate for 
apoB-48-containing lipoproteins is very high compared to that for apoB-100-containing 
lipoproteins (Li, 1996), concentrations of VLDL and LDL are very low in wild-type mice 
and rats compared to humans. In reverse cholesterol transport from peripheral tissue to 
the liver, high-density lipoproteins (HDLs) receive free cholesterol from macrophages 
through scavenger receptor type B-I (SR-BI) and ABCs such as ABCA1 (Rohrer, 2009). The 
free cholesterol transported from macrophages is esterified by lecithin:cholesterol 
acyltransferase (LCAT) in plasma. The esterified cholesterol in HDL particles is 
transferred to VLDL, IDL, and LDL in plasma by cholesterol ester transfer protein (CETP) 
in humans and rabbits (Son, 1986), while mice and rats do not have CETP activity in 
plasma (Agellon, 1991). Therefore, the cholesterol ester in HDL particles is not transferred 
to apoB-containing lipoproteins in mice and rats. This is one of the major reasons why 
HDL is the predominant lipoprotein in these two species. Circulating HDL particles bind 
to SR-BI in the liver. Therefore, the large difference in lipoprotein metabolism between 
mice / rats and humans / rabbits is characterized by both the expression of apobec-1 in the 
liver and absence of CETP in the plasma of mice and rats. Dyslipidemia develops when 
lipoprotein metabolism is impaired. For example, LDLR deficiency causes familial 
hypercholesterolemia, and impaired LPL function causes hypertriglyceridemia. A number 
of animal models including transgenic animals, knockout animals, and spontaneous 
mutant animals can develop hypercholesterolemia, hypertriglyceridemia, and 
postprandial hypertriglyceridemia. However, the lipoprotein profile of these mice is 
greatly different from that of human patients. 
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Figure 2. Lipoprotein metabolism in mice and rats (wild-type). Abbreviations: ACAT, acyl-
CoA:cholesterol acyltransferase; apoB, apolipoprotein B; CETP, cholesterol ester transfer protein; Chyl, 
chylomicron; CR, chylomicron remnant; DGAT2, acyl-Co-A:diacylglycerol acyltransferase 2; ER, apoE 
receptor; FABP, fatty acids-binding protein; FFA, free fatty acids; H, high-density lipoprotein; HL, 
hepatic lipase; I48, intermediate-density lipoprotein (IDL) with apoB-48; I100, IDL with apoB-100; L, 
low-density lipoprotein (LDL); LCAT, lecithin:cholesterol acyltransferase; LPL, lipoprotein lipase; LR, 
LDL receptor; M, macrophage; MTP, microsomal triglyceride transfer protein; NPC1L1, Niemann-Pick 
C1-like 1; PLTP, phospholipid transfer protein; SR-BI, scavenger receptor type B-I; V48, very low-
density lipoprotein (VLDL) with apoB-48; V100, VLDL with apoB-100; VR, VLDL receptor 
3. Genetically modified animal models as tools for studying lipoprotein 
metabolism 
Genetically modified animals for studying lipoprotein metabolism are summarized in Table 
1. The list includes genetically modified mice, rats, rabbits, and chicken, but not double- or 
triple-modified animals. Several double- or triple-modified mice were developed by cross-
breeding, for example, the apoE/LDLR-dKO mouse, the apoE/SRBI-dKO mouse, and others. 
Genetically modified animals can be good tools for clarifying the role of genes in lipoprotein 
metabolism and atherosclerosis if researchers take into consideration species differences. 
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 Transgenic animals Knockout animals 
 mouse rat rabbit mouse rat chick 
Apolipoprotein 
apoA-I Walsh, 1989 Swanson, 1992 Duverger, 1996 Plump, 1997 
apoA-II Marzal-Casacub, 1996 Koike, 2009 Weng, 1996 
apoB100 Farese, 1995  Fan, 1995 Young, 1995 
apoC-I Simonet, 1991   Gautier, 2002 
apoC-II Shachter, 1994 
apoC-III Aalto-Setala, 1992  Ding, 2011 
apoC-IV Allan, 1996 
apoE Shimano, 1992  Fan, 1998 Piedrahita, 1992 
apo(a) Chiesa, 1992  Rouy, 1998 
apoM Christoffersen, 2008  Christoffersen, 2008 
Cholesterol absorption in intestine 
NPC1L1     Altmann, 2004   
ABCA1     McNeish, 2003   Mulligan, 2003 
ACAT1     Buhman, 2000 
Apobec 1     Kendrick, 2001 
MTP     Xie, 2006 
PLTP     Liu, 2007 
SR-BI     Mardones, 2001 
FABP     Newberry, 2009 
tis7 Wang, 2005 
VLDL secretion from liver 
DGAT2     Liu, 2008   
MTP     Raabe, 1998 
Apobec-1     Morrison, 1996 
Lipolytic enzyme 
LPL Shimada, 1993  Fan, 2001 Coleman, 1995 
HL Braschi, 1998  Fan, 1994 Gonzalez-Navarro, 2004 
EL Ishida, 2003;  Ishida, 2003; Ma, 2003 
Lipoprotein metabolism 
LDLR Hofmann, 1998  Ishibashi, 1993  Asahina, 2012 
PCSK9 Herbert, 2010    Rashid, 2005 
VLDLR     Frykman, 1995 
SR-type A     Suzuki, 1997 
Reverse cholesterol transport 
ABCA1 Vaisman, 2001    McNeish, 2000 
ABCG1 Kennedy, 2005    Kennedy, 2005 
SR-BI Wang, 1998    Rigotti, 1997 
LCAT Vaisman, 1995  Hoeg, 1996 
CETP Aggellon, 1991 Herrera, 1999 
PLTP Jiang, 1996  Masson, 2011 Jiang, 1999 
Table 1. List of genetically modified animals regarding lipoprotein metabolism. 
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3.1. Cholesterol absorption in the intestine 
Recent studies using genetically modified animals have help to clarify the mechanism of 
cholesterol absorption in the jejunum. Dietary cholesterol forms micelles with bail acids in the 
lumen of the jejunum, which are then transported through NPC1L1. Thereafter, the free 
cholesterol is esterified by acyl coenzyme A:cholesterol acyltransferase 2 (ACAT2) and 
chylomicron particles are formed by the packaging of esterified cholesterol, triglyceride, and 
apolipoprotein B by MTP (Hussain, 2012). NPC1L1 was found by Altman et al (2002). 
NPC1L1, highly expressed in the jejunum and located on the surface of absorptive enterocytes, 
is critical for the intestinal absorption of dietary and biliary cholesterol (Altmann, 2004). 
NPC1L1 mediates cholesterol uptake through vesicular endocytosis. Davis et al (2004) 
produced NPC1L1 KO mice, which had substantially reduced intestinal uptake of cholesterol 
and sitosterol. NPC1L1-deficiency resulted in the up-regulation of intestinal 
hydroxymethylglutaryl-CoA synthase mRNA expression and an increase in intestinal 
cholesterol synthesis, the down-regulation of ABCA1 mRNA expression, and no change in 
ABCG5 and ABCG8 mRNA levels. Therefore, NPC1L1 is required for intestinal uptake of both 
cholesterol and phytosterols and plays a major role in cholesterol homeostasis. These findings 
in NPC1L1-KO mice were similar to results obtained with an inhibitor of cholesterol 
absorption, ezetimibe (Garcia-Calvo, 2005). Phospholipid transfer protein (PLTP) is also 
involved in cholesterol absorption in the intestine (Liu R, 2007). PLTP-KO mice absorb 
significantly less cholesterol than wild-type mice. In addition, mRNA levels of NPC1L1 and 
ABCA1 and MTP activity levels were significantly decreased in the small intestine of PLTP-KO 
mice. The free cholesterol taken up through NPC1L1 and PLTP is esterified by ACAT2. 
Experiments with ACAT2-KO mice demonstrated that a deficiency of ACAT2 activity inhibits 
cholesterol absorption in the intestine (Buhman, 2000). In the intestine, lipids absorbed are 
packaged with apolipoproteins and form chylomicron particles. The major structural 
apolipoprotein in chylomicron particles is apoB-48. ApoB-48 is produced by apobec-1, which 
inserts a stop codon. A deficiency of apobec-1 in the intestine resulted in reduction in the 
secretion and assembly of chylomicron particles (Kendrick, 2001). These results from apobec-1-
KO mice suggested that apoB-48 is involved in the assembly of chylomicron particles (Lo, 
2008). Finally, absorbed lipids and synthesized apolipoproteins are assembled by MTP. MTP-
KO mice demonstrated a decrease in cholesterol absorption and chylomicron secretion, in 
addition to manifestations of steatorrhea (Xie, 2006). Although ABC and SR-BI were 
considered important to cholesterol absorption until the year 2000, SR-BI is not essential for 
intestinal cholesterol absorption (Mardones, 2001). Cholesterol absorption was independent of 
ABCA1 in KO mice (McNeish, 2000) and ABCA1-mutant chickens (Mulligan, 2003). Thus, 
studies with genetically modified animals have verified the mechanisms of dietary lipid 
absorption revealed by experiments in vitro.  
3.2. Formation and secretion of VLDL particles from liver 
The liver is the main organ in lipoprotein metabolism. Endogenous lipoprotein (VLDL) 
particles are produced in liver. The production and secretion of VLDL consist of the 
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synthesis of cholesterol, triglyceride, phospholipids, and apolipoproteins, and assembly of 
these components. As described, apobec-1 is expressed in the liver in mice and rats, but not 
in humans and rabbits. Therefore, apoB-48-containing VLDL particles are secreted from the 
mouse and rat liver. Compared to those containing apoB-100, VLDL particles containing 
apoB-48 are rapidly cleared from circulation through apoER expressed on hepatocytes, 
similar to chylomicron remnants (Fig 2). To better approximate human lipoprotein 
metabolism, apobec-1-deficient mice were developed by gene targeting (Morrison, 1996). 
The LDL levels increased and HDL levels decreased in the circulation. However, 
overexpression of human apoB-100 showed different results between mice and rabbits. 
Plasma cholesterol levels decreased in apoB-100-overexpresing mice (Farese, 1996), although 
plasma cholesterol, triglyceride, and LDL levels increased and HDL levels decreased in 
apoB-100-overexpressing rabbits (Fan, 1995). This difference may be due to differences in 
CETP activity in the circulation between mice and rabbits. In addition, suppression of acyl-
CoA: diacylglycerol acyltransferase 2 (DGAT2) expression by antisense treatment decreased 
VLDL secretion in mice (Liu, 2008). This suggests that suppression of triglyceride synthesis 
decreases VLDL secretion. Studies using inhibitors of MTP suggested that MTP plays a key 
role in the production of VLDL particles and inhibition of MTP activity decreases VLDL 
secretion in WHHL rabbits (Shiomi, 2001). Indeed, MTP+/- mice fed a high-fat diet 
demonstrated decreased levels of apoB-containing lipoproteins in plasma (Raabe, 1998). 
Furthermore, hepatocytes synthesize and/or secrete a lot of apolipoproteins, such as apoA, 
apoB, apoC, apoE, apoM, and apo(a). The function of these apolipoproteins has been 
clarified using genetically modified animals. However, influences of the overexpression of 
apoB, apoE, and apo(a) differ between mice and rabbits. ApoE overexpression resulted in a 
marked decrease in non-HDL cholesterol in mice (Shimano, 1992), while in rabbits, 
cholesterol of LDL and HDL increased and the fractional catabolic rate of chylomicron also 
increased (Fan, 1998). These differences between mice and rabbits may be due to CETP 
activity and the expression of abobec-1 in mouse liver. Lipoprotein (a), an atherogenic 
lipoprotein, is formed by the binding of apo(a) to LDL particles and is detected in plasma of 
only humans and monkeys. In human-apo(a) transgenic mice (Chiesa, 1992), apo(a) does not 
bind to mouse LDL particles, while human apo(a) binds to rabbit LDL particles and 
lipoprotein (a) is also atherogenic in rabbits (Rouy, 1998; Fan, 1999). Therefore, the role of 
endogenous apoB-containing lipoproteins (VLDL, IDL, and LDL) in the regulation of 
plasma lipid levels differs between genetically modified mice and rabbits or humans. 
3.3. Lipolysis of apoB-containing lipoproteins  
Lipoproteins are transporters in circulation that provide cholesterol as a material for steroid 
hormones and the cytoskeleton, and triglycerides (fatty acids) for energy to peripheral 
tissue. In the transportation of fatty acids, lipoprotein lipase (LPL), hepatic lipase (HL), and 
endothelial lipase (EL) function at capillaries and apoC affects lipolytic activities. LPL 
mediates the lipolysis of VLDL and chylomicrons, and these lipoprotein particles are 
transformed into IDL and chylomicron remnants, respectively. Although LPL-/- mice die 
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within a day after birth because of dramatic hypertriglyceridemia, impaired fat tolerance, 
and hypoglycemia (Weinstock, 1995), these LPL-KO mice could be rescued by transient LPL 
expression induced by adenoviral-mediated gene transfer (Strauss, 2001). Rescued adult 
LPL-KO mice exhibit severe hypertriglyceridemia as patients with homozygous LPL-
deficiency. LPL+/- mice showed increases in plasma triglyceride levels due to increases in 
the fraction of VLDL and chylomicrons in the circulation. Overexpression of LPL in mice 
(Shimada, 1993) and rabbits (Fan, 2001) caused decreases in plasma triglyceride, VLDL, and 
LDL levels, in addition to the suppression of atherosclerotic lesions (Shimada, 1996). ApoC-I 
modulates this metabolism. Although knockout of apoC-I gene did not affect serum lipid 
levels, expression of human CETP markedly increased levels of cholesterol ester in plasma, 
VLDL, and LDL in apoC-I-KO mice (Gautier, 2002). In contrast, in transgenic mice 
overexpressing human apoC-I, plasma triglyceride and total cholesterol levels were 
increased compared to those in wild-type mice. In addition, overexpression of apoC-I, apoC-
II, apoC-III, and apoC-IV also increased plasma triglyceride and total cholesterol levels, and 
suppressed LPL activity in mice (Simonet, 1991; Shachter, 1994; Aalto-Setala, 1992; Allan, 
1996) and rabbits (Ding, 2011). HL modulates the metabolism of both apoB-containing and 
apoA-containing lipoproteins. In apoE-KO mice, deficiency of HL showed a decrease in the 
fractional catabolic rate of apoB-48-containing VLDL, IDL and LDL despite no effects on 
apoB-100-containing LDL, in addition to increases in total cholesterol and triglyceride levels 
in apoB-containing and apoA-containing lipoproteins (Mezdour, 1997 & Gonzalez-Navarro 
H, 2004). However, development of atherosclerotic lesions was reduced in HL-KO mice. In 
HL-transgenic mice (Brashci, 1998) and rabbits (Fan, 1994), catabolism of both HDL and 
apoB-48-containing lipoproteins is enhanced, and plasma total cholesterol and triglyceride 
levels are decreased. Therefore, HL may be associated with catabolism of not only apoB-
containing lipoproteins but HDL. EL is located in arterial endothelial cells and has 
phospholipase activity against phospholipids in HDL particles (Broedl, 2003; Ishida, 2003). 
EL hydrolyzes phospholipids on HDL particles and promotes catabolism of HDL. 
Overexpression of EL decreases in HDL cholesterol and apoA-I levels decreased in mice 
(Ishida, 2003; Jaye, 1999). By contrast, a deficiency of EL increases HDL levels (Ishida, 2003; 
Ma, 2003), in addition to atherogenic action (Ishida, 2004) and allergic asthma (Otera, 2009). 
Another study confirmed the high HDL-C levels in EL-/- mice but did not document an 
association with atherosclerosis (Ko, 2005). Thus, the role of EL in reverse cholesterol 
transport and atherosclerosis has not been fully elucidated. Further studies are required to 
clarify the function of EL in the metabolism of HDL and atherosclerosis. In studies about 
lipolysis, genetically modified animals have demonstrated no species differences, and are 
useful in this field.  
3.4. Receptor-mediated catabolism of apoB-containing lipoproteins 
3.4.1. LDL receptor 
Lipoprotein receptors, such as LDLRs, VLDL receptors (VLDLRs), apoE receptors (remnant 
receptors, apoERs), and scavenger receptors (SRs), take up lipoprotein particles into 
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parenchymal cells and/or phagocytes. LDLRs are expressed on the surface of parenchymal 
cells and bind to circulating LDL. The ligands are apoB-100 and apoE. A deficiency or the 
suppression of LDLRs results in the accumulation of LDL in the circulation, a condition 
known as human familial hypercholesterolemia. Several animal models for LDLR-deficiency 
have been developed. One of the better known models is the WHHL (Watanabe, 1980) or 
WHHLMI (Shiomi, 2003; 2009) rabbit. WHHL or WHHLMI rabbits show 
hypercholesterolemia due to LDLR deficiency even when fed standard chow. However, 
LDLR-KO mice (Ishibashi, 1993 & 1994) and LDLR-KO rats (Asahina, 2012) showed mildly 
increased serum cholesterol levels. Sanan et al. (1998) reported that LDLR-KO mice 
expressing human apoB-100 showed hypercholesterolemia due to the accumulation of LDL 
in the plasma even in chow feeding. In addition, Teng et al (1997) demonstrated that 
adenovirus-mediated gene delivery of apobec-1 reduced plasma apoB-100 levels, leading to 
the almost complete elimination of LDL particles and a reduction in LDL cholesterol in 
LDLR-KO mice. These studies suggests that the absence of any increase in plasma 
cholesterol levels in LDLR-KO mice is due to the expression of apobec-1 in the liver and 
apoB-100-containing LDL is a key player in LDLR deficiency to increased plasma cholesterol 
levels. Expression of LDLRs on the cell surface is regulated by proprotein convertase 
subtilisin/kexin type 9 (PCSK9). Recently, Huijgen et al. (2012) reported that plasma levels of 
PCSK9 were associated with LDL cholesterol levels in patients with familial 
hypercholesterolemia. In addition, overexpression of PCSK9 induced negative modulation 
of LDLR expression and decreased plasma LDL clearance, also promoting atherosclerosis 
(Herbert, 2010). In contrast, knockout of PCSK9 resulted in an increase in the LDL receptor 
protein (Mbikay, 2010) and a decrease in plasma cholesterol levels (Rashid, 2005). 
Furthermore, PCSK9 regulates the expression of not only LDLRs but VLDLRs and apoERs 
(Poirier, 2008). Therefore, PCSK9 can be considered a new target in the treatment of 
hypercholesterolemia. 
3.4.2. VLDL receptor 
VLDL particles are incorporated through VLDLRs. VLDLRs are expressed in heart, muscle, 
adipose tissues, and macrophages but not in liver in humans and rabbits. In mice, however, 
VLDLRs are not expressed in macrophages (Takahashi, 2011), suggesting the process of 
atherogenesis to be somewhat different between mice and humans or rabbits. Knockout of 
VLDLRs does not affect lipoprotein metabolism but decreases body weight, BMI, and 
epididymal fat in mice (Frykman, 1995). In addition, LPL activity is decreased by VLDLR-
deficiency. These observations suggest VLDLRs to be associated with metabolic syndrome. 
Furthermore, a recent study suggests that the expression of VLDLRs is affected by PCSK9 
(Roubtsova, 2011). Surprisingly, adipose tissues of apoE-KO mice did not express LDLR, 
VLDLR, and LDLR-related proteins (Huang, 2009), although wild-type mice developed 
these receptors in adipose tissue. Since the VLDLR has various functions, genetically 
modified animals may contribute to further studies. 
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3.4.3. Remnant receptor 
Remnant receptors are mainly expressed in liver and contribute to the metabolism of 
exogenous lipoproteins, which contain apoB-48, in humans and rabbits. Therefore, down-
regulation of remnant receptor function causes the accumulation of chylomicron remnants 
in plasma. As their ligand is apolipoprotein E, remnant receptors are also called apoE 
receptors (apoERs). In mice and rats, VLDL, IDL, and LDL contain apoB-48 due to the 
expression of apobec-1 in the liver. These apoB-48-containing lipoproteins bind to apoERs 
through interaction with the apoE ligand and disappear from the circulation rapidly. The 
fractional catabolic rate for apoB-48-containing VLDL is remarkably high compared to that 
for apoB-100-containing VLDL (Gonzalez-Navarro, 2004). This is one of the reasons why 
concentrations of VLDL and LDL are very low in plasma of mice and rats. In contrast, apoE-
KO mice have very high VLDL concentration and the VLDL fraction consists of apoB-48 
(Gonzalez-Navarro, 2004). Since apoE is a ligand of apoER, lipoproteins containing only 
apoB-48 cannot bind to apoERs in apoE-KO mice. This is the reason for the 
hypercholesterolemia in apoE-KO mice. Consequently, the hypercholesterolemia of apoE-
KO mice due to the accumulation of apoB-48-containing lipoproteins is different from 
human hypercholesterolemia due to the accumulation of apoB-100-containing lipoproteins. 
This difference affects the development of hypocholesterolemic agents.  
3.4.4. Scavenger receptor type A 
Scavenger receptor type A (SR-A) is expressed on phagocytes and plays an important role in 
the removal of modified lipoproteins, such as oxidized-LDL, acetyl-LDL, and glycated-LDL. 
Therefore, SR-A plays an important role in atherogenesis. Knockout of SR-A decreases the 
uptake of modified LDL, but does not affect plasma lipid levels (Suzuki, 1997).  
3.5. Reverse cholesterol transport 
The plasma concentration of HDL is inversely related to the risk of atherosclerotic vascular 
diseases. HDL plays a key role in the reverse transport of cholesterol from peripheral tissue 
to liver. Recent studies suggest that HDL is also associated with anti-inflammation, anti-
thrombosis, anti-oxidation, and the enhancement of endothelial function. Newly 
synthesized apoA-I binds to ABCs (particularly ABC-A1) or SR-BI of macrophages and 
takes up free cholesterol from macrophages. The complex of apoA-I and free cholesterol is 
transformed into discoidal nascent HDL (pre-β HDL). These nascent HDLs become HDL 
particles (HDL3) after esterification of the free cholesterol by LCAT in plasma. In the process 
of the transformation from discoidal HDL to HDL3, HDL takes up apoE and free cholesterol 
from macrophages mainly by ABCG1. Therefore, as the HDL matures, its cholesterol 
content increases. In humans and rabbits, CETP in plasma exchanges the cholesterol ester of 
HDL particles with triglyceride in apoB-containing lipoproteins. Therefore, peripheral 
cholesterol is transported by two pathways; an LDLR pathway mediated by CETP function 
and a SR-BI pathway. However, mice and rats do not have CETP activity in plasma. 
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Therefore, the pathway of reverse cholesterol transport is markedly different between mice / 
rats and humans / rabbits. 
3.5.1. Apolipoproteins of HDL particles 
HDL particles contain apoA, apoC, apoE, and apoM. ApoA, the main structural 
apolipoprotein of HDL particles, is mainly classified as apoA-I, apoA-II, and apoA-IV. 
ApoA and apoE play an important role in the efflux of cholesterol from macrophages to 
discoidal and small HDL, respectively. Recent studies suggested that apoM is related to the 
anti-oxidative function of HDL (Elsoe, 2012).  
ApoA-I is a major structural apolipoprotein of HDL particles. ApoA is synthesized mainly 
in the liver and intestine, and from HDL particles hydrolyzed by HL. Humans and mice 
have two types of HDLs. One contains only apoA-I and the other, both apoA-I and apoA-II. 
However, rabbit HDLs are apoA-I particles (Chapman, 1980 & Koike, 2009). ApoA-I plays 
an important role in the reverse transport of cholesterol. Overexpression of apoA-I increases 
HDL-cholesterol levels in mice (Walsh, 1989), rats (Swanson, 1992), and rabbits (Duverger, 
1996). In contrast, knockout of the apoA-I gene in mice decreases cholesterol levels in HDL, 
VLDL, and whole plasma (Plump, 1997). In addition, apoA-I-deficient HDL is a poor 
substrate for HL and LCAT. These studies using genetically modified animals indicate that 
apoA-I plays an important role in cholesterol reverse transport. Another major 
apolipoprotein of HDL is apoA-II. Overexpression of human apoA-II in mouse liver resulted 
in a decrease in plasma cholesterol levels due to a decrease in HDL cholesterol but an 
increase in plasma triglyceride levels (Marzal-Casacub, 1996). In addition, LCAT activity 
and mouse apoA-II levels in plasma were decreased in human apoA-II transgenic mice. 
Consequently, the changes in plasma lipid levels in human apoA-II transgenic mice may be 
due to a reduction in levels of mouse apoA-II. These results suggest species differences in 
apoA-II. In addition, apoA-II is dimer in human but monomer in mice. Knockout of apoA-II 
in mice resulted in a decrease in not only HDL-cholesterol but non-HDL cholesterol. In 
addition, the fractional catabolic rate for apoA-I was increased by a deficiency of apoA-II 
(Weng, 1996). Furthermore, the deficiency was associated with lower free fatty acid, glucose, 
and insulin levels, suggesting insulin hypersensitivity, while apoA-II does not relate to 
insulin sensitivity in humans. Therefore, the function of apoA-II is very confusing in mouse 
models. Conversely, rabbits overexpressing human apoA-II, which do not have apoA-II, 
lipid levels in plasma and non-HDL lipoproteins were increased but HDL-cholesterol levels 
and activities of LPL and HL were decreased (Koike, 2009). Therefore, effects of human 
apoA-II overexpression may be different between mice and rabbits. To clarify the function 
of apoA-II, more studies are required. 
3.5.2. Transfer of cholesterol from macrophages to HDL 
The start of the reverse cholesterol transport process is the transfer of cholesterol from 
macrophages to apoA-I, in which ABCs play important roles. Several strains of mice with 
genetically modified ABCA1 and ABCG1 have been produced. Overexpression of ABCA1 in 
mice increases cholesterol efflux from macrophages, in addition to increases in levels of 
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cholesterol, apoA-I, and apoA-II in HDL (Vaisman, 2001). In contrast, ABCA1-KO mice 
showed a marked decrease in HDL-cholesterol, LDL-cholesterol, and plasma apoB levels, 
and an absence of apoA-I in plasma, but an increase in cholesterol absorption and the 
accumulation of lipid-laden macrophages (McNeish, 2000). Furthermore, in ABCG1-KO 
mice, cholesterol efflux from macrophages to HDL is decreased (Kennedy, 2005). After its 
efflux from macrophages to apoA-I and HDL, free cholesterol is esterified by LCAT in the 
plasma. Overexpression of LCAT in mice increases levels of cholesterol, apoA-I, apoA-II, 
and apoE in plasma, in addition to HDL cholesterol (Vaisman, 1995). LCAT-overexpressing 
rabbits showed an increase in HDL-cholesterol on a chow diet but non-HDL cholesterol was 
not increased on a cholesterol diet (Hoeg, 1996). Therefore, LCAT plays an important role in 
the esterification of free cholesterol in HDL. Studies using ABCA1-KO mice, ABCG1-KO 
mice, and ABCA1/ABCG1-dKO mice (Out, 2008) have elucidated how cholesterol is 
transported from macrophages to HDL. ApoE also promotes reverse cholesterol transport 
by enhancing the efflux of free cholesterol from peripheral macrophages to maturing HDL 
particles (Hayek, 1994). The efflux of free cholesterol to apoE-binding HDL is mediated by 
ABCG1/4 (Matsuura, 2006). The efflux from macrophages to apoE-containing HDL3 (small 
HDL particles) depends on apoE. HDL-cholesterol levels are markedly low in apoE-KO 
mice, despite being high HDL in wild-type mice (Zhang, 1992). Therefore, the low HDL-
cholesterol levels in apoE-KO mice are due to a decrease in the efflux of cholesterol from 
macrophages to HDL. By contrast, the overexpression of apoE induced a marked decrease in 
apoB-containing lipoproteins in mice (Shimano, 1992), but human apoE3 overexpression 
increased cholesterol levels in not only HDL but LDL in rabbits (Fan, 1998). These 
differences between mice and rabbits are due to the activity of CETP in plasma, since no 
CETP activity is detected in mice but strong activity is found in rabbits. 
3.5.3. Transfer of lipids from HDL to apoB-containing lipoproteins 
One of the main courses of reverse cholesterol transport depends on CETP in plasma in 
human and rabbits (Son, 1986). However, mice and rats do not have CETP activity in plasma 
(Agellon, 1991). Therefore, in mice, the HDL cholesterol level is high but cholesterol levels of 
apoB-containing lipoproteins are markedly low. Overexpression of human CETP in mice 
induces a decrease in HDL-cholesterol but no changes in cholesterol levels in VLDL and 
LDL (Agellon, 1991). Similar findings were made in Dahl rats (Herrera, 1999). One of the 
reasons for no changes in cholesterol levels of non-HDL fraction is due to a rapid clearance 
of apoB-48-containing lipoproteins through apoER. These results suggest that CETP 
transfers cholesterol ester from HDL to apoB-containing lipoproteins. Furthermore, CETP 
expression led to atherosclerosis in Dahl rats fed a cholesterol diet. Therefore, CETP-
overexpression can cause complex responses depending on diet. PLTP is a plasma protein, 
which transfers phospholipids from apoB-containing lipoproteins to HDL. Knockout of 
PLTP resulted in a decrease in cholesterol (Jiang, 1999; 2001). In PLTP transgenic mice, PLTP 
did not affect lipid levels of apoB-containing lipoproteins but increased phospholipid and 
cholesterol levels in HDL (Jiang, 1996). However, overexpression of PLTP in rabbits 
increased cholesterol levels in apoB-containing lipoproteins but had no effect on HDL lipids 
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in a high-cholesterol deiet feeding (Masson, 2011). These differences in the function of PLTP 
between mice and rabbits may be due to fundamental differences in lipoprotein metabolism, 
such as CETP activity in the plasma and apobec-1 expression in the liver. Therefore, one has 
to be deliberate in interpreting results from gene modification studies. 
3.5.4. HDL receptors 
HDL particles are incorporated by SR-BI, a HDL receptor, expressed in liver. In humans and 
rabbits, cholesterol is transferred from peripheral macrophages to liver through two 
pathways, via CETP-LDLR and SR-BI, while in mice and rats, cholesterol is transported to 
liver via SR-BI expressed in liver. Overexpression of SR-BI in mice induces a decrease in 
plasma lipids and an increase in the fractional catabolic rate for HDL (Wang, 1998). In 
contrast, SR-BI-KO mice show increases in plasma cholesterol levels, HDL particle size, and 
levels of apoE and apoA-I in HDL particles (Rigotti, 1997). These results demonstrate the 
function of SR-BI in reverse cholesterol transport. However, these changes in plasma lipid 
levels reflect HDL lipid levels, because mice do not have CETP activity in the plasma.  
4. Species differences in phenotypes between genetically modified 
animals  
Table 2 shows species differences in phenotypes of lipoprotein metabolism between 
genetically modified animals when the same genes were modified. Overexpression of apoB-
100 increased HDL-cholesterol but had no effect on non-HDL-cholesterol in mice fed a chow 
diet (Farese, 1996) but increased in cholesterol levels in plasma and LDL in rabbits (Fan, 
1995). Overexpression of apoE decreased levels of apoB-containing lipoproteins in mice 
(Shimano, 1992) but increased cholesterol levels in plasma and LDL in rabbits (Fan, 1998). In 
addition, overexpression of PLTP increased HDL-cholesterol and apoA-I levels but did not 
affect LDL-cholesterol in mice (Jiang, 1996), while it increased LDL-cholesterol and did not 
affect HDL in rabbits (Masson, 2011). These differences may be due to high CETP activity in 
rabbits and no CETP activity in mice. Lipoprotein(a) is detected in humans and monkeys, 
and is an atherogenic lipoprotein. In mice overexpressing human apo(a) (Chiesa, 1992), 
apo(a) did not bind to mouse LDL particles, while in rabbits, human apo(a) can bound to 
rabbit LDL particles and formed Lp(a) (Rouy, 1998; Fan, 1999). Finally, LDLR-KO increased 
cholesterol levels mildly in plasma and LDL in mice (Ishibashi, 1993) and rats (Asahina, 
2012), while spontaneous LDLR-deficient rabbits (WHHL or WHHLMI rabbits) show severe 
hypercholesterolemia due to the accumulation of LDL in plasma even on a normal diet 
(Goldstein, 1993; Shiomi, 2003; 2009). In humans, LDLR-deficiency produces severe 
hypercholesterolemia due to the accumulation of LDL in plasma. These differences in effects 
of LDLR between humans / rabbits and mice / rats may be due to the expression of apobec-1 
in the liver and CETP activity in the plasma. Therefore, one has to consider species 
differences when using animal models. LDLR-KO mice on a high-fat diet showed dramatic 
hypercholesterolemia (Ishibashi, 1994), and the plasma cholesterol level is comparable with 
or higher than that of apoE-KO mice. In contrast, the degree of atherosclerosis is greater in 
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apoE-KO mice than LDLR-KO mice. In addition, LDLR-KO mice on a chow diet did not 
show massive atherosclerotic lesions at the age of 12 months (Ishibashi, 1994), while apoE-
KO mice on a chow diet for the same period showed massive atherosclerotic lesions (Zhang, 
1992 and Reddick, 1994). These differences in plasma lipid profiles and atherosclerosis are 
not fully understood but are likely to be attributable to the quality or subtype of the 
circulating lipoproteins.  
Genes modification Mice and/or rats Rabbits 
Apo-B100 overexpression 
Increase in HDL-cholesterol 
and no effect on non-HDL-
cholesterol on chow feeding 
Increase in plasma and LDL 
cholesterol 
Apo-E overexpression 
Decrease in non-HDL 
cholesterol 
Increase in plasma and LDL 
cholesterol 
Apo (a) overexpression Not bind to mouse LDL 
Binds to rabbit LDL and 
forms Lp(a) 
PLTP overexpression 
Increase in HDL-cholesterol 
and apoA-I but no effects on 
LDL-cholesterol 
Increase in LDL-cholesterol 
but no effect on HDL 
LDLR-deficiency 
Mild increase in plasma 
cholesterol 
Marked increase in plasma 
cholesterol 
Table 2. Species differences in phenotype on overexpression of the same genes. 
5. Genetically modified animal models for human dyslipidemia  
Table 3 summarizes plasma lipid profiles of genetically modified animal models for human 
dyslipidemia. Plasma lipid and/or lipoprotein profiles of genetically modified mice resemble 
those for human diseases involving apoC-II deficiency, LPL deficiency, and CETP deficiency. 
However, plasma lipid levels and lipoprotein profiles of genetically deficient mice are 
markedly different from those of humans with a deficiency of ABCA1, apoE or LDLR. In 
ABCA1-KO mice, cholesterol levels markedly decreased in not only HDL but whole plasma, 
while patients with Tangier disease, who do not have ABCA1 and show very low levels of 
HDL-cholesterol, exhibit a mild decrease in plasma cholesterol levels. This difference 
between ABCA1-KO mice and patients with Tangier disease may be due to CETP activity in 
plasma. ApoE-KO mice fed normal chow show hypercholesterolemia and the increased 
lipoprotein fraction is VLDL, which contains apoB-48, although plasma triglyceride levels are 
almost normal. In addition, HDL-cholesterol levels are markedly low. However, patients 
with apoE deficiency show type III hyperlipidemia by the WHO classification. The increased 
lipoprotein is VLDL and IDL, and both cholesterol and triglyceride levels are increased. HDL 
cholesterol is almost normal (Mabuchi, 1989). These differences in lipoprotein metabolism 
between mice and patients may be due to the expression of apobec-1 in mouse liver and the 
triglyceride content of the VLDL fraction. Considering these observations, the 
hypercholesterolemia in apoE-KO mice may not reflect human hypercholesterolemia. In 
LDLR deficiency, although humans and rabbit models show marked hypercholesterolemia 
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due to the accumulation of LDL in plasma despite a normal diet (Watanabe, 1980; Shiomi, 
2009), the accumulation of LDL in plasma in homozygous LDLR-KO mice is mild (Ishibashi, 
1993; 1994). These differences in plasma lipid levels and lipoprotein profiles between LDLR-
KO mice and familial hypercholesterolemia or WHHL rabbits are due to the rapid clearance 
of apoB-48-containing VLDL, IDL, and LDL through apoER in mouse liver. Recently, LDLR-
KO rats were developed (Asahina, 2012) . These animals have a similar lipoprotein profile to 
LDLR-KO mice. Studies demonstrate that both the expression of apobec-1 in liver and a 
deficiency of CETP in plasma greatly affect lipoprotein metabolism and plasma lipid levels in 
mice and rats. To solve these problems with LDLR-KO mice and apoE-KO mice, cross 
breeding with apobec-1-KO/CETP-expressing animals may be required in studies of 
lipoprotein metabolism. In the development of statins, potent anti-hyperlipidemic agents 
used by more than 40 million patients world-wide, no cholesterol-lowering effect was 
observed in mice and rats, although strong cholesterol-lowering effects were found in rabbits, 
dogs, monkeys and chickens (Tsujita, 1986). In addition, simvastatin, a statin, did not 
decrease serum cholesterol levels in LDLR-KO mice and CETP(+/-)LDLR(-/-)mice, and 
increased serum cholesterol levels in apoE-KO mice at a dose of 30 mg/kg/day (Yin, 2012), 
although an extremely high dose of statins (0.168% in diet, 200-300 mg/kg/day) decreased 
serum cholesterol levels in LDLR-KO mice (Krause, 1998). In contrast, WHHL rabbits, an 
animal model of familial hypercholesterolemia, have played important roles in studies of the 
hypocholesterolemic effects and anti-atherosclerotic effects of statins (Shiomi, 1995; 2009). The 
cholesterol-lowering effect of statins is mainly mediated by an increase in LDLR in liver. 
Therefore, the effect is weak when the contribution of LDLR to the regulation of plasma 
cholesterol levels is small, as in mice and rats. These studies suggest the need to select animal 
models based on study purposes. 
Gene modification Mice and/or rats Human 
ABCA1 deficiency 
Marked decrease in cholesterol 
levels in both plasma and HDL 
Tangier disease, 
Marked decrease in HDL 
cholesterol but mild decrease in 
plasma cholesterol 
apoC-II deficiency Hypertriglyceridemia Hypertriglyceridemia 
apoE-deficiency 
Hypercholesterolemia 
Increase in VLDL and decrease in 
HDL 
Combined hyperlipidemia 
Increase in IDL and no changes 
in HDL 
LDLR-deficiency 
Mild increase in plasma cholesterol
Mild increase in LDL 
Hypercholesterolemia 
Marked increase in LDL 
LPL deficiency 
Hypertriglyceridemia 
Lethal right after birth in 
homozygotes 
Hypertriglyceridemia 
CETP deficiency 
High HDL cholesterol (wild-type 
mice) 
High HDL cholesterol 
Table 3. Plasma lipid profiles of genetically modified animal models for human dyslipidemia 
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6. Conclusion 
In this chapter, the authors summarized achievements of studies using genetically modified 
animal models in lipoprotein research. The cross-breeding of genetically modified animals, 
such as double KO mice, triple KO mice, and others, has contributed to studies of 
lipoprotein metabolism. Studies using genetically modified mice have elucidated the 
mechanisms of cholesterol absorption in the intestine, lipolysis of apoB-containing 
lipoproteins, lipoprotein receptor function, and cholesterol efflux from macrophages to 
HDL. Although genetically modified animals are useful to elucidate the function of genes 
related to lipoprotein metabolism, we have to carefully select animal species to know the 
effect of these genes on lipid levels of whole plasma and lipoprotein profiles in humans. In 
addition, genetically modified mice have limitations in studies about the development of 
hypocholesterolemic agents, because of the expression of apobec-1 in liver and a deficiency 
of CETP activity in plasma. Consequently, these fundamental differences in lipoprotein 
metabolism between mice and humans affect the interpretation of results of gene 
modification about lipoprotein metabolism in mice. To solve these problems, genetically 
modified mice should be produced using CETP-transgenic/apobec-1-KO mice or animals 
having a background of no expression of apobec-1 in the liver and expression of CETP in 
plasma. We have to be careful in the interpretation of results obtained using genetically 
modified animals, and to select animal models in response to study purposes to extrapolate 
the results to humans. Recently, techniques of X-linked severe combined immunodeficiency 
(X-SCID) using zinc-finger nucleases, transcriptional activator-like effector nucleases 
(TALEN), and mutation using an N-ethyl-N-nitrosourea mutagenesis have become available 
for knockout gene expression. These techniques will be able to produce KO-animals other 
than mice. These animals will contribute further to studies of lipoprotein metabolism and 
lipid disorders in humans. 
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